Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.

Although targeting of cancer cells using drug-delivering nanocarriers holds promise for improving therapeutic agent specificity, the strategy of maximizing ligand affinity for receptors overexpressed on cancer cells is suboptimal. To determine design principles that maximize nanocarrier specificity...

Full description

Bibliographic Details
Main Authors: Konstantinos Tsekouras, Igor Goncharenko, Michael E Colvin, Kerwyn Casey Huang, Ajay Gopinathan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3694107?pdf=render
id doaj-25e7da70d9bb4413baed8e3c9d3dad8d
record_format Article
spelling doaj-25e7da70d9bb4413baed8e3c9d3dad8d2020-11-24T21:55:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0186e6562310.1371/journal.pone.0065623Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.Konstantinos TsekourasIgor GoncharenkoMichael E ColvinKerwyn Casey HuangAjay GopinathanAlthough targeting of cancer cells using drug-delivering nanocarriers holds promise for improving therapeutic agent specificity, the strategy of maximizing ligand affinity for receptors overexpressed on cancer cells is suboptimal. To determine design principles that maximize nanocarrier specificity for cancer cells, we studied a generalized kinetics-based theoretical model of nanocarriers with one or more ligands that specifically bind these overexpressed receptors. We show that kinetics inherent to the system play an important role in determining specificity and can in fact be exploited to attain orders of magnitude improvement in specificity. In contrast to the current trend of therapeutic design, we show that these specificity increases can generally be achieved by a combination of low rates of endocytosis and nanocarriers with multiple low-affinity ligands. These results are broadly robust across endocytosis mechanisms and drug-delivery protocols, suggesting the need for a paradigm shift in receptor-targeted drug-delivery design.http://europepmc.org/articles/PMC3694107?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Konstantinos Tsekouras
Igor Goncharenko
Michael E Colvin
Kerwyn Casey Huang
Ajay Gopinathan
spellingShingle Konstantinos Tsekouras
Igor Goncharenko
Michael E Colvin
Kerwyn Casey Huang
Ajay Gopinathan
Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.
PLoS ONE
author_facet Konstantinos Tsekouras
Igor Goncharenko
Michael E Colvin
Kerwyn Casey Huang
Ajay Gopinathan
author_sort Konstantinos Tsekouras
title Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.
title_short Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.
title_full Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.
title_fullStr Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.
title_full_unstemmed Design of High-Specificity Nanocarriers by Exploiting Non-Equilibrium Effects in Cancer Cell Targeting.
title_sort design of high-specificity nanocarriers by exploiting non-equilibrium effects in cancer cell targeting.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Although targeting of cancer cells using drug-delivering nanocarriers holds promise for improving therapeutic agent specificity, the strategy of maximizing ligand affinity for receptors overexpressed on cancer cells is suboptimal. To determine design principles that maximize nanocarrier specificity for cancer cells, we studied a generalized kinetics-based theoretical model of nanocarriers with one or more ligands that specifically bind these overexpressed receptors. We show that kinetics inherent to the system play an important role in determining specificity and can in fact be exploited to attain orders of magnitude improvement in specificity. In contrast to the current trend of therapeutic design, we show that these specificity increases can generally be achieved by a combination of low rates of endocytosis and nanocarriers with multiple low-affinity ligands. These results are broadly robust across endocytosis mechanisms and drug-delivery protocols, suggesting the need for a paradigm shift in receptor-targeted drug-delivery design.
url http://europepmc.org/articles/PMC3694107?pdf=render
work_keys_str_mv AT konstantinostsekouras designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting
AT igorgoncharenko designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting
AT michaelecolvin designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting
AT kerwyncaseyhuang designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting
AT ajaygopinathan designofhighspecificitynanocarriersbyexploitingnonequilibriumeffectsincancercelltargeting
_version_ 1725860754372952064